Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines

Patent metadata

Field	Value
Publication number	US-9730943-B2
Application number	US-201113885038-A
Country	US
Kind code	B2
Filing date	Nov 8, 2011
Priority date	Nov 11, 2010
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

First claim

The invention claimed is:

1. A compound of formula (I):

wherein:
R 1 is —(CH 2 ) n —(CHR 4 )—(CH 2 ) m —N(R 5 )(R 5 );
R 2 is a heteroaryl of structure:

wherein:
* indicates the point of attachment of said heteroaryl to the rest of the structure of formula (I);

R 3 is C 1 -C 3 -alkyl substituted with 1 R 8 group;
R 4 is hydroxy;
R 5 and R 5′ are independently a hydrogen atom or a C 1 -C 3 -alkyl group;
or
R 5 and R 5′ are taken together with the nitrogen atom to which they are bound to form a 5- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen and sulfur and which is optionally substituted with 1 or more R 6′ groups;
each occurrence of R 6 and R 6′ is independently a hydrogen atom or a methyl group;
R 8 is aryl; and
n is an integer of 1 and m is an integer of 1,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing.

2. The compound according to claim 1 , wherein:
R 1 is —(CH 2 ) n —(CHR 4 )—(CH 2 ) m —N(R 5 )(R 5 );
R 2 is a heteroaryl of structure:

wherein:
* indicates the point of attachment of said heteroaryl to the rest of the structure of formula (I);

R 3 is C 1 -C 3 -alkyl substituted with 1 R 8 group;
R 4 is hydroxy;
R 5 and R 5′ are taken together with the nitrogen atom to which they are bound, to form a 5- to 7-membered nitrogen containing heterocyclic ring containing one oxygen atom, which is optionally substituted with 1 or more R 6′ groups;
each occurrence of R 6 and R 6′ is independently a hydrogen atom or a methyl group;
each occurrence of R 8 is aryl; and
n is an integer of 1 and m is an integer of 1,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing.

3. A compound selected from the group consisting of:
N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide;
N-{8-({(2R)-3-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide;
N-{7-[2-(4-Fluorophenyl)ethoxy]-8-[2-hydroxy-3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide;
rel-2-amino-N-{8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxy-2-methylpropyl}oxy)-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; and
rel-N-{8-({(2R)-3-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-2-hydroxy-2-methylpropyl}oxy)-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1 , and a pharmaceutically acceptable diluent or carrier.

5. A pharmaceutical combination comprising:
one or more compounds of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1 ; and
one or more agents selected from: a taxane, Docetaxel, Paclitaxel, or Taxol; an epothilone, Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2′-deoxyadenosine; Thioguanine; an anti-androgen, Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

Assignees

• Scott William Johnston
• Möwes Manfred
• Liu Ningshu
• Mönning Ursula
• Bömer Ulf
• Bayer Ip Gmbh

Inventors

• Scott William Johnston
• Möwes Manfred
• Liu Ningshu
• Mönning Ursula
• Bömer Ulf

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title